NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE ® (triamcinolone acetonide injectable suspension) ...
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback